A Case Report of Kidney After Heart Transplant in Patient With Fabry Disease

Transplant Proc. 2023 Oct;55(8):1975-1977. doi: 10.1016/j.transproceed.2023.07.009. Epub 2023 Aug 8.

Abstract

Fabry disease is an X-linked inherited lysosomal storage disorder caused by a mutation in the gene encoding the enzyme α-galactosidase A. It is characterized by the accumulation of globotriaosylceramide in different tissues, resulting in a wide range of clinical presentations. Fabry cardiomyopathy and Fabry nephropathy are the disease's 2 most important life-threatening manifestations and can contribute to higher morbidity and mortality. Heart and kidney transplants can play a major role in patients with Fabry disease who develop end organ damage. We report a case of a successful heart transplant in a male patient with Fabry disease at the age of 62, followed by a kidney transplant later at the age of 69. He has had an uneventful post-transplant course and has been tolerating maintenance immunosuppression and enzyme replacement therapy with recombinant human α-galactosidase A.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Enzyme Replacement Therapy
  • Fabry Disease* / complications
  • Fabry Disease* / surgery
  • Heart Transplantation* / adverse effects
  • Humans
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Treatment Outcome
  • alpha-Galactosidase / therapeutic use

Substances

  • alpha-Galactosidase